Not so long ago, Hoffmann-La Roche Inc. faced a grim reality in sprawling litigation over the acne medication Accutane.
In 2007, New Jersey judge Carol Higbee handed an edge to plaintiffs lawyers at Seeger Weiss, Weitz & Luxenberg and other plaintiffs firms, allowing their causation expert to testify about links between Accutane and forms of inflammatory bowel disease (IBD). Soon afterward, the plaintiffs were boasting a string of multi-million dollar verdicts.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
